California Board of Pharmacy Attorney Fee Petition Mechanics: Tyler Odyssey Civil Complaint Date as Primary Welch Anchor, CBP BreEZe License Verification Database as Secondary Institutional Anchor (the Only CBP BreEZe Module Anchor in This Series — Covering Registered Pharmacists [RPh], Pharmacy Technicians [CPhT], Pharmacy Interns, and Pharmacies as Entities by License Number, Issue Date, Expiration Date, and Clear/Revoked/Suspended Status), CLRA § 1780 Mandatory Attorney Fees for Patients Who Received Prescription Drugs or Compounded Preparations from Unlicensed Practitioners Including Schedule II–V Controlled Substances Dispensed Without DEA Controlled Substance Registration Authority — Simultaneous § 4060 State Violation and 21 U.S.C. § 829 Federal CSA Violation with No Federal Private Fee-Shifting (Pure Ketchum)

Statutory Framework: Bus. & Prof. Code § 4060 and the California Pharmacy Law — CBP License Requirements, Prohibited Conduct, and CLRA § 1780 Mandatory Attorney Fees for Unlicensed Pharmacy Practice

California Business and Professions Code § 4060 is the operative licensure prohibition of the California Pharmacy Law (Bus. & Prof. Code §§ 4000–4427), establishing that no person may dispense, furnish, or compound a dangerous drug or dangerous device in California without first obtaining and maintaining a current license issued by the California Board of Pharmacy. CBP administers California's pharmacy licensure program as a division of the Department of Consumer Affairs (DCA) under the authority of the DCA Director, maintaining its licensing records through the BreEZe license management system. CBP's licensing jurisdiction encompasses: Registered Pharmacists (RPh, the core pharmacy practitioner license — issued upon passage of the NAPLEX [North American Pharmacist Licensure Examination] and MPJE [Multistate Pharmacy Jurisprudence Examination], or through reciprocity for pharmacists already licensed in other states; RPh licenses require biennial renewal with completion of continuing pharmacy education under 16 CCR § 1732.1); Pharmacy Technicians (CPhT, registration required for any pharmacy technician who performs functions delegated by a supervising pharmacist, including prescription data entry, label generation, medication counting and packaging, and dispensing activities under pharmacist supervision; CPhT registration requires a national pharmacy technician examination such as PTCE or ExCPT and a CBP registration); Pharmacy Interns (PharmD intern registration, issued to students enrolled in accredited pharmacy programs under Bus. & Prof. Code § 4209, authorizing limited practice activities under direct pharmacist supervision during clinical rotations); and Pharmacies as entities (PHY entity licenses, issued under § 4110, required for each discrete pharmacy location — a standalone pharmacy, a hospital outpatient pharmacy, a mail-order pharmacy, a compounding-only pharmacy, or a specialty pharmacy — with a designated Pharmacist-in-Charge (PIC) whose RPh license number is recorded in the CBP BreEZe entity record and who is responsible for all pharmacy operations, compliance with the California Pharmacy Law, and DEA Schedule II–V controlled substance security and record-keeping).

The scope of violations triggering § 4060 civil liability and CLRA § 1780 mandatory fee-shifting encompasses multiple distinct patterns of unlicensed pharmacy practice with qualitatively different harm profiles for patients: (1) individuals with no CBP RPh license — medical assistants, nursing home aides, personal care attendants, wellness clinic staff, herbal medicine practitioners, or online supplement retailers — who dispense, furnish, or hand off prescription medications to patients without CBP licensure, particularly in contexts where the dispensing is masked by a "physician dispensing" or "in-office dispensing" framework that exceeds what Bus. & Prof. Code § 4170 authorizes; (2) former CBP licensees whose RPh licenses have expired, been revoked, or been placed on suspension — pharmacists who continue to practice dispensing, refill prescriptions, or provide compounding services without disclosing their unlicensed status to patients who believe they are receiving services from a currently licensed pharmacist; (3) individuals operating compounding-only laboratories or "nutraceutical compounding" services without CBP entity (PHY) licensure — producing and dispensing bulk compounded preparations (including hormone replacement therapy [HRT] preparations, pain management topical compounds, sterile injectable preparations, and veterinary compounding repackaged for human use) without CBP pharmacy entity licensure, DEA registration, or USP 797/800 sterile/hazardous compounding compliance; (4) online or mail-order pharmacy operations that ship prescription medications to California residents without a CBP-issued mail-order pharmacy license under § 4112 — a violation triggered by shipment of any dangerous drug to a California address regardless of the state in which the online pharmacy is located; and (5) cannabis dispensary operators who also dispense non-cannabis prescription medications without CBP licensure, relying on the cannabis regulatory framework of the Department of Cannabis Control (DCC) as a substitute for the CBP licensure required for prescription drug dispensing under § 4060.

The CLRA civil remedy arises because pharmacy services — the dispensing, furnishing, and compounding of prescription medications and dangerous devices — are consumer services purchased by patients for personal and family health use, satisfying the definition of "consumer services" under Civil Code § 1761(b). Every unlicensed pharmacy practitioner who represents themselves as CBP-licensed — using RPh designation, PharmD credential, or CBP license number on prescription receipts, refill labels, or patient medication profiles, or operating from a pharmacy setting that patients reasonably believe to be staffed by a CBP-licensed pharmacist — impliedly represents current CBP licensure, a representation that constitutes a misrepresentation of service provider qualifications under Civil Code § 1770(a)(14) when the practitioner lacks a current Clear CBP license. The "shall award" language of CLRA § 1780(e) eliminates judicial discretion and establishes CLRA § 1780 as a pure mandatory fee statute for unlicensed pharmacy practice claims. UCL § 17200 provides a parallel per se unlawful business practice theory — unlicensed pharmacy practice is an unlawful business act as a per se violation of § 4060 — supporting restitution of all dispensing fees, compounding charges, and prescription payments made to the unlicensed practitioner and injunctive relief against continued credential misrepresentation.

Three Unique Distinctions in the Fee-Petition-Mechanics Series

• THE ONLY CBP (California Board of Pharmacy) BreEZe License Verification Database anchor in the entire fee-petition-mechanics series — distinct from the BRN BreEZe module for Registered Nurses, the BVNPT BreEZe module for Licensed Vocational Nurses and Psychiatric Technicians, the MBC BreEZe module for Medical Doctors, the PAB BreEZe module for Physician Assistants, and every other DCA healing arts board BreEZe module in the series — covering Registered Pharmacists (RPh, the core dispensing license), Pharmacy Technicians (CPhT registration), Pharmacy Interns (PharmD intern registration), and Pharmacies as entities (PHY entity licenses with Pharmacist-in-Charge designation) — each by CBP license number, issue date, expiration date, and Clear/Expired/Revoked/Suspended/Probation/Inactive status: the California Board of Pharmacy BreEZe module is the only CBP-specific DCA BreEZe module in the fee-petition-mechanics series — a BreEZe module covering a qualitatively distinct professional category (pharmacy practitioners and pharmacy entity operations, with licensure requirements specific to the dispensing, furnishing, and compounding of dangerous drugs and devices) from all other DCA healing arts board modules in the series; the CBP BreEZe module records each licensee's CBP license number (RPh prefix for Registered Pharmacists, with a sequential state-assigned license number distinct from the DEA CSR number; PHY prefix for pharmacy entities, with a location-specific entity license number recording the pharmacy's designated Pharmacist-in-Charge by RPh license number; TCH prefix for pharmacy technicians; INT prefix for pharmacy interns), licensee name and business name (for PHY entity licenses), license type (RPh — Pharmacist; PHY — Pharmacy; TCH — Pharmacy Technician; INT — Intern Pharmacist), issue date, expiration date (biennial renewal with CBP-approved continuing pharmacy education under 16 CCR § 1732.1, currently requiring 30 hours per biennial period including pharmacist-in-charge [PIC] requirements of 2 hours in law and 2 hours in drug product selection and formulary), and current status (Clear — license in good standing, the licensee is authorized to dispense and compound within the scope of their license type; Expired — license lapsed past the biennial renewal deadline without timely reinstatement, and the licensee is not authorized to practice; Revoked — CBP discipline resulting in license revocation following administrative accusation and hearing proceedings under the Administrative Procedure Act, Gov. Code § 11500 et seq., typically predicated on professional incompetence, drug theft or diversion under Bus. & Prof. Code § 4301(j), criminal conviction involving moral turpitude or controlled substance violations, or fraudulent dispensing practices; Suspended — temporary suspension pending investigation or as a disciplinary outcome; Probation — licensee practicing under CBP probationary terms and conditions, often including community supervision, drug testing, practice restrictions, and employer notification requirements; Inactive — licensee who has voluntarily placed the license on inactive status and is not currently practicing); the CBP BreEZe module is distinct from every other DCA healing arts board BreEZe module in the series in that it covers both individual practitioner licenses (RPh, CPhT, intern) and entity licenses (PHY pharmacies as discrete business locations), enabling the attorney to verify both the individual pharmacist's RPh license status and the pharmacy entity's PHY license status — a dual verification approach that establishes § 4060 violations at both the individual practitioner level and the operating entity level simultaneously; the Pharmacist-in-Charge (PIC) designation recorded in each PHY entity's CBP BreEZe record is particularly important in fee petition mechanics because it identifies the specific licensed pharmacist who was designated as responsible for all pharmacy operations at the entity location, creating a direct CBP accountability link between the PHY entity license and the individual RPh licensee responsible for the dispensing activities — if the PIC's RPh license was revoked, suspended, or expired during the period of the challenged dispensing transactions, the attorney documents both the individual PIC's unlicensed status and the PHY entity's resulting lack of a qualified PIC, establishing § 4060 violations at both levels from the same CBP BreEZe search.
• THE ONLY page where unlicensed practice involves Schedule II–V controlled substance dispensing without DEA Controlled Substance Registration (CSR) authority — a simultaneous § 4060 California Pharmacy Law violation AND 21 U.S.C. § 829 federal Controlled Substances Act violation — with victim class including opioid patients (hydrocodone/oxycodone/fentanyl/tramadol — Schedule II–III), benzodiazepine patients (alprazolam/diazepam/lorazepam/clonazepam — Schedule IV), stimulant patients (amphetamine salts/methylphenidate — Schedule II), sleep medication patients (zolpidem/eszopiclone — Schedule IV–IV), and medical cannabis patients receiving controlled analogues — all of whom received Schedule II–V medications without mandatory pharmacist drug-interaction screening, therapeutic duplication check, and 16 CCR § 1707.2 mandatory patient consultation required of all CBP-licensed pharmacists: California pharmacy law requires that every pharmacist dispensing a Schedule II–V controlled substance must, in addition to holding a current RPh license, operate within a DEA-registered pharmacy entity (a PHY entity holding a valid DEA Certificate of Registration [CSR] issued to the pharmacy location's DEA registration number under 21 C.F.R. § 1301.11); an unlicensed pharmacy practitioner dispensing Schedule II–V controlled substances simultaneously violates § 4060 of the California Pharmacy Law (dispensing without CBP licensure) and 21 U.S.C. § 829 of the federal Controlled Substances Act (dispensing a controlled substance without a valid DEA CSR or pursuant to a valid prescription issued by a DEA-registered practitioner within a legitimate practitioner-patient relationship); the federal CSA violation (21 U.S.C. § 829) does NOT create a private right of action with mandatory fee-shifting for the injured patient — 21 U.S.C. § 843 criminalizes unlawful dispensing of controlled substances with criminal penalties of up to 4 years imprisonment (first offense), but no federal statute (not the CSA, not the Ryan Haight Act [21 U.S.C. § 831], not the SUPPORT Act [Pub. L. 115-271]) creates a private civil action for patients harmed by unlicensed controlled substance dispensing; the sole civil private action with mandatory fee-shifting for the patient is CLRA § 1780, PURE KETCHUM, because the dispensing of dangerous drugs including controlled substances is a consumer service under Civil Code § 1761(b); the victim class in § 4060 / CLRA § 1780 controlled substance dispensing cases encompasses: (a) opioid patients who received Schedule II hydrocodone/oxycodone combinations (Vicodin, Percocet equivalents) or Schedule II fentanyl preparations or Schedule III tramadol from an unlicensed dispenser without the mandatory pharmacist drug-interaction screening (including potential fatal interactions with benzodiazepines, alcohol, and other CNS depressants that a CBP-licensed pharmacist is required to check under the DUR [Drug Utilization Review] protocol of 16 CCR § 1746); (b) benzodiazepine patients who received Schedule IV alprazolam (Xanax equivalent), diazepam (Valium equivalent), lorazepam (Ativan equivalent), or clonazepam (Klonopin equivalent) from an unlicensed dispenser without the CBP-required DUR check for respiratory depression risk (particularly when co-prescribed with opioids — the FDA Black Box Warning combination that requires specific pharmacist counseling under 16 CCR § 1707.2); (c) stimulant patients who received Schedule II amphetamine salts (Adderall equivalent) or methylphenidate (Ritalin equivalent) for ADHD management without the CBP-required pharmacist verification of prescriber DEA authority and prescription legitimacy under the Ryan Haight Act (21 U.S.C. § 831), particularly in telehealth contexts where prescriptions may have been written by prescribers who lacked California DEA registration or valid California prescriber licensure; (d) sleep medication patients who received Schedule IV zolpidem (Ambien equivalent) or eszopiclone (Lunesta equivalent) without the CBP-required pharmacist screening for dangerous drug interactions with alcohol, opioids, and other CNS depressants, and without the mandatory patient consultation required by 16 CCR § 1707.2 regarding daytime somnolence, fall risk, and driving impairment; the harm profile for Schedule II–V controlled substance victims is qualitatively more severe than the harm profile in most other pages in the fee-petition-mechanics series — opioid dispensing without pharmacist DUR screening creates overdose death risk (particularly when combined with benzodiazepines or alcohol), and benzodiazepine dispensing without DUR screening creates respiratory depression and fall injury risk for elderly patients, creating a damages spectrum that extends from pharmacist negligence claims to wrongful death claims alongside the CLRA § 1780 mandatory fee entitlement.
• THE ONLY page where unlicensed pharmacy practice in a compounding context creates simultaneous ADULTERATION and MISBRANDING liability under California Health and Safety Code § 111295 (adulterated drug or device) and § 111330 (misbranded drug or device) in addition to the § 4060 licensing violation and CLRA § 1780 consumer protection claim — patients who received compounded preparations from an unlicensed compounder may have received medications of unknown potency, sterility, or identity, with harm spectrum from therapeutic failure to sterility-related infection to catastrophic overdose: California pharmacy law distinguishes between licensed compounding pharmacies (CBP-licensed PHY entity pharmacies that may compound non-sterile preparations under USP Chapter <795> standards and sterile preparations under USP Chapter <797> standards, with CBP inspection authority under Bus. & Prof. Code § 4127 et seq.) and unlicensed compounding operations; when an unlicensed practitioner engages in pharmacy compounding — preparing hormone replacement therapy (HRT) preparations (bioidentical estrogen/progesterone/testosterone topical creams, troches, and sublingual preparations), pain management topical compounds (diclofenac/ketamine/gabapentin/clonidine combinations), sterile injectable preparations (vitamin injection cocktails, peptide preparations, PRP preparations), or veterinary preparations repackaged for human use — without CBP licensure, the compounded preparation simultaneously constitutes: (a) an adulterated drug under Health and Safety Code § 111295 — because the preparation was not manufactured under CBP-required pharmacy compounding standards (USP <795> for non-sterile, USP <797> for sterile preparations) and may have been prepared in a facility without the clean room requirements, equipment calibration standards, Beyond Use Date (BUD) determination protocols, and potency testing required for compliant pharmacy compounding; (b) a misbranded drug under Health and Safety Code § 111330 — because the compounded preparation lacks the labeling requirements mandated by Bus. & Prof. Code § 4076 for prescription drug labels, including the prescribing practitioner's name, the dispensing pharmacy's CBP license number, the patient's name, and the Beyond Use Date; and (c) a § 4060 dangerous drug dispensed by an unlicensed person, triggering the CLRA § 1780 mandatory fee entitlement; the harm profile for unlicensed compounding victims encompasses: (a) potency failures — HRT preparations compounded without analytical potency testing may contain dramatically different concentrations of bioidentical hormones than labeled, creating endocrine disruption, breakthrough bleeding, cardiovascular events (for excess estrogen), or androgenic side effects (for excess testosterone); (b) sterility failures — sterile injectable preparations compounded without USP <797> environmental monitoring, personnel training, and aseptic technique standards may be contaminated with bacterial or fungal pathogens, creating injection-site abscesses, bacteremia, sepsis, meningitis (for intrathecal preparations), or endophthalmitis (for ophthalmic injections) — the type of catastrophic sterility failures that caused the 2012 New England Compounding Center (NECC) fungal meningitis outbreak that killed 64 patients from contaminated methylprednisolone acetate preparations; (c) Beyond Use Date violations — preparations dispensed past the CBP-required BUD without retesting create degradation products, microbial contamination, and therapeutic failure risks invisible to the patient; and (d) cross-contamination failures — unlicensed compounders who prepare potent compounded medications (chemotherapy agents, controlled substance preparations) in the same facility as other preparations without CBP-required containment protocols create cross-contamination risks that may expose patients to trace amounts of cytotoxic or psychoactive substances not described on the preparation label; the adulteration and misbranding liability creates both a separate cause of action under Health and Safety Code § 111295 / § 111330 (civil penalty of $250–$500 per violation under Health and Safety Code § 111940, enforceable by the California Attorney General, local District Attorney, or city attorney) and a reinforcing CLRA § 1780 predicate, because the misbranded preparation label constitutes a misrepresentation of service characteristics under Civil Code § 1770(a)(5) (representing that goods have uses, ingredients, benefits, or quantities that they do not have) — the CLRA and adulteration claims are complementary rather than duplicative, and both are PURE KETCHUM with no federal fee-shifting statute providing a parallel remedy (the DQSA FDA outsourcing facility oversight framework creates no private civil right of action for compounding injury victims).

PURE KETCHUM — Bus. & Prof. Code § 4060 / CLRA § 1780 unlicensed pharmacy practice claims with no concurrent federal statute providing mandatory civil attorney fee-shifting; no Ketchum/Dague split for the CLRA § 1780 lodestar: no federal statute creates a private right of action with mandatory attorney fees for patients harmed by unlicensed California pharmacy practice. The federal Controlled Substances Act (21 U.S.C. § 829) criminalizes dispensing Schedule II–V controlled substances without a valid DEA Controlled Substance Registration but provides no private civil right of action with mandatory fee-shifting for injured patients. The federal Drug Quality and Security Act (DQSA, Pub. L. 113-54, enacted 2013) established FDA oversight of compounding outsourcing facilities (503B facilities) and traditional compounding pharmacies (503A) but created no private civil enforcement mechanism for patients harmed by unlicensed compounding — FDA enforcement is limited to administrative seizure, injunction, and criminal prosecution. The federal Ryan Haight Online Pharmacy Consumer Protection Act (21 U.S.C. § 831) requires that online pharmacies obtain a DEA registration and comply with the legitimate prescriber-patient relationship requirement for controlled substance prescriptions but creates no private fee-shifting remedy for patients who received controlled substances from unlicensed online dispensers. The federal Food, Drug, and Cosmetic Act (FDCA, 21 U.S.C. § 331 et seq.) prohibits misbranded and adulterated drugs in interstate commerce but provides no private right of action for individual patients (see Buckman Co. v. Plaintiffs' Legal Committee, 531 U.S. 341 (2001)). For the CLRA § 1780 unlicensed pharmacy practice claim, the entire lodestar from the CBP BreEZe search date through the Tyler Odyssey complaint through judgment is PURE KETCHUM, eligible for the full Ketchum v. Moses (24 Cal.4th 1122 (2001)) contingency multiplier without any Dague v. City of Hamtramck (505 U.S. 557 (1992)) constraint on any portion of the fee award.

Primary Welch Anchor: Tyler Odyssey Civil Complaint Filing Date

The Tyler Odyssey civil complaint filing date is the primary Welch temporal anchor for the CLRA § 1780 attorney fee petition lodestar in Bus. & Prof. Code § 4060 unlicensed pharmacy practice cases. In unlicensed pharmacy matters, the Tyler Odyssey complaint is typically filed after the plaintiff attorney has: confirmed through the CBP BreEZe License Verification Database that the defendant pharmacist lacks a current Clear RPh license, or that the defendant pharmacy entity lacks a current Clear PHY entity license with a qualified Pharmacist-in-Charge; reviewed the defendant's prescription records, dispensing logs, refill documentation, compounding worksheets, and patient medication profiles to confirm the specific § 4060 violations and the specific credential misrepresentations made to the patient; assessed the harm profile for the patient's specific medication category — controlled substance DUR failures, compounding potency and sterility failures, or prescription dispensing without mandatory consultation under 16 CCR § 1707.2; and evaluated the complete patient harm spectrum, from prescription dispensing fee refund to physical injury damages to wrongful death damages where opioid or compounding failures caused catastrophic patient harm.

The pre-complaint advisory period in unlicensed pharmacy cases can be initiated through multiple discovery pathways: a patient who, when researching their pharmacist's credentials following an adverse drug event (medication error, drug interaction, or allergic reaction that a licensed pharmacist should have screened), searches the CBP BreEZe database and discovers that the individual who dispensed their medications lacks a current Clear RPh license or that the pharmacy entity lacks a current Clear PHY entity license; a patient who received compounded preparations — particularly sterile injectable preparations, HRT topical compounds, or controlled substance compounded formulations — and suffered an adverse health event (infection, therapeutic failure, or overdose) traceable to the compounded preparation's potency or sterility failure, leading them to investigate the compounding facility's CBP licensure status; a patient who received controlled substance prescriptions (opioids, benzodiazepines, or stimulants) through a telehealth or concierge medical service's in-office dispensing program and discovers that the individual who dispensed the medications was not a CBP-licensed pharmacist; a patient who received prescription medications through an online pharmacy that shipped to their California address and discovers, upon investigation, that the online pharmacy did not hold a CBP-issued mail-order pharmacy license under Bus. & Prof. Code § 4112; or a patient who received prescription medications through a cannabis dispensary's ancillary medical services program and discovers that the non-cannabis prescription drug dispensing was conducted without CBP licensure separate from the DCC cannabis retailer license held by the dispensary operator.

The Tyler Odyssey complaint in unlicensed pharmacy cases typically pleads: (1) a CLRA § 1780 claim predicated on § 4060 unlicensed pharmacy practice — a per se misrepresentation of service provider qualifications under Civ. Code § 1770(a)(14) for the RPh or pharmacist credential representation; (2) a UCL § 17200 unlawful business practice claim predicated on the § 4060 violation — supporting restitution of all dispensing fees and compounding charges; (3) professional negligence claims for DUR and mandatory consultation failures causing physical injury; (4) in controlled substance dispensing cases, a negligence per se claim predicated on the 21 U.S.C. § 829 federal CSA violation and the § 4060 California Pharmacy Law violation; and (5) in unlicensed compounding cases, an adulteration and misbranding liability claim under Health and Safety Code § 111295 / § 111330, with Health and Safety Code § 111940 statutory penalties supporting punitive damages analysis under Civil Code § 3294.

Secondary Institutional Anchor: CBP BreEZe License Verification Database

The California Board of Pharmacy BreEZe License Verification Database is the secondary institutional anchor in CLRA § 1780 unlicensed pharmacy practice fee petition cases — THE ONLY CBP BreEZe module anchor in the entire fee-petition-mechanics series. The CBP BreEZe module records each licensee's: CBP license number (RPh prefix for Registered Pharmacists, PHY prefix for Pharmacy entities, TCH prefix for Pharmacy Technicians, INT prefix for Pharmacy Interns), licensee name and (for PHY entities) pharmacy business name and physical address, license type, issue date, expiration date (biennial renewal with continuing pharmacy education under 16 CCR § 1732.1), current status (Clear, Expired, Revoked, Suspended, Probation, or Inactive), and any disciplinary actions posted on the CBP BreEZe public profile (Citations issued under Bus. & Prof. Code § 125.9 for minor violations, Accusations filed by the California Attorney General on behalf of CBP, and Final Orders of the CBP Board issued after administrative hearing proceedings).

The attorney verifying the defendant's CBP licensure performs a dual-level search: first, a CBP BreEZe search for the individual practitioner's RPh license — confirming the RPh license status (Clear, Expired, Revoked, Suspended, or Probation) as of each date the challenged dispensing transactions occurred, and reviewing any disciplinary actions on the BreEZe public profile that may document prior CBP findings of § 4060 violations, drug diversion, or professional incompetence; second, a CBP BreEZe search for the operating pharmacy entity's PHY license — confirming the PHY entity license status, the Pharmacist-in-Charge (PIC) designation (by RPh license number), and the physical address of the pharmacy location at which the challenged dispensing occurred (relevant to confirming the location was licensed as a dispensing pharmacy rather than operating as an unlicensed drug dispensary). In cases involving unlicensed compounding operations, the attorney also searches the CBP BreEZe entity database for any pharmacy entity license covering the compounding facility's address — confirming whether the compounding operation was conducted without a PHY entity license or with a PHY entity license that did not cover compounding activities (a license scope violation distinct from the license status violation).

The CBP BreEZe database is distinct from every other DCA healing arts board BreEZe module in the fee-petition-mechanics series in that it covers both individual practitioner licenses (RPh, CPhT, intern) and entity licenses (PHY pharmacies), enabling dual-level CBP verification that establishes § 4060 violations at the individual pharmacist level and at the operating pharmacy entity level simultaneously. The entity-level PHY license verification — with the Pharmacist-in-Charge identification — is a unique feature of the CBP BreEZe module unavailable in any other DCA healing arts board BreEZe module in the series, because CBP is the only DCA board that licenses both individual practitioners and the physical operating locations (pharmacies) in which they practice, creating an organizational accountability structure in which both the individual RPh and the operating PHY entity must maintain current Clear CBP licensure for any dispensing transaction to be lawfully authorized.

Billing Gap 1 — CBP BreEZe License Search, DEA CSR Verification, § 4060 Unlicensed Pharmacy Analysis, Drug Interaction Harm Assessment, and Controlled Substance Harm Spectrum Evaluation (5.25 hrs/yr = $1,575–$2,625)

The first billing gap arises in the pre-complaint advisory phase — from initial patient contact through Tyler Odyssey complaint filing — during which the attorney searches CBP BreEZe for both individual RPh licensure and PHY entity licensure, verifies DEA CSR status for controlled substance dispensing cases, reviews the defendant's prescription records and compounding worksheets, and assesses the full patient harm spectrum including DUR failures, compounding potency and sterility failures, and the controlled substance victim class harm profile.

• Searching CBP BreEZe License Verification Database for individual RPh license status and PHY entity license status — confirming license type, issue date, expiration date, Pharmacist-in-Charge designation (for PHY entities), current status (Clear/Expired/Revoked/Suspended/Probation), and any disciplinary actions posted on BreEZe public profile — and cross-referencing with CBP disciplinary records, Citations, and Final Orders: the attorney performs the CBP BreEZe search at two levels: individual RPh practitioner and operating PHY entity; for the individual RPh, confirming: RPh license number, current status (Clear, Expired, Revoked, Suspended, or Probation) as of each relevant dispensing date, the biennial expiration date (confirming whether the license was current and renewed through the challenged period), and any BreEZe-posted disciplinary actions (Citations for minor violations, Accusations filed by the California AG on CBP's behalf, and Final Orders resulting from administrative hearings — any prior CBP discipline for drug diversion, unprofessional conduct, or § 4060 violations corroborates the fee petition's unlicensed practice narrative and supports enhanced Ketchum multiplier arguments); for the operating PHY entity, confirming: PHY entity license number, physical address (confirming the licensed location matches the location where the challenged dispensing occurred), Pharmacist-in-Charge RPh license number (enabling the attorney to cross-reference the PIC's individual RPh status), current status, and any disciplinary actions; cross-referencing the CBP BreEZe search results against the defendant's representations — RPh or PharmD credential designations on prescription receipts, refill labels, compounding worksheets, or patient medication profiles; CBP license numbers printed on pharmacy prescription bags or patient medication education handouts; and "Licensed Pharmacist" or "CBP Licensed" designations on the defendant's website, social media profiles, or clinic marketing materials — documents the specific misrepresentations of CBP licensure inducing patient reliance on the unlicensed practitioner.
• Verifying DEA Controlled Substance Registration (CSR) status for controlled substance dispensing cases — confirming DEA registration number, schedules authorized (II, III, IV, V), registrant name (individual or entity), and registration status (Active, Expired, or Revoked) — and cross-referencing with the specific Schedule II–V controlled substances dispensed by the defendant to the patient (opioids, benzodiazepines, stimulants, sleep medications): in cases involving Schedule II–V controlled substance dispensing, the attorney verifies the defendant's DEA Controlled Substance Registration status through the DEA Diversion Control Division's registration verification system — confirming: DEA registration number (assigned to each registrant location under 21 C.F.R. § 1301.11), DEA registrant name and business name (confirming the registration corresponds to the defendant's pharmacy location), DEA schedule authorizations (confirming whether the DEA CSR authorizes dispensing of the specific scheduled substances at issue — e.g., a DEA Schedule III-V pharmacy registration would not authorize dispensing Schedule II hydrocodone or oxycodone), registration status (Active, Expired, or Revoked), and registration expiration date (DEA pharmacy registrations require annual renewal); cross-referencing the DEA registration status against the specific controlled substances dispensed — for opioid victims, confirming that the defendant lacked DEA CSR authority to dispense the specific Schedule II hydrocodone/oxycodone or Schedule III tramadol preparations at issue; for benzodiazepine victims, confirming the Schedule IV alprazolam/diazepam/lorazepam dispensing was unauthorized; for stimulant victims, confirming the Schedule II amphetamine/methylphenidate dispensing violated 21 U.S.C. § 829; the DEA CSR verification establishes the simultaneous federal CSA violation (21 U.S.C. § 829) and California § 4060 violation, reinforcing the CLRA § 1780 predicate while confirming that the federal violation creates no parallel private fee-shifting remedy — establishing the PURE KETCHUM status from both the California and federal law perspectives.
• Assessing the patient harm spectrum for drug interaction failures, compounding potency and sterility failures, and mandatory consultation violations (16 CCR § 1707.2 consultation requirement) — including opioid/benzodiazepine co-dispensing DUR failures, sterile compounding infection injuries, HRT compounding potency failures, and controlled substance dispensing without prescriber verification: the attorney assesses the complete patient harm spectrum arising from the § 4060 violation: (a) DUR (Drug Utilization Review) failures under 16 CCR § 1746 — the CBP-licensed pharmacist's mandatory obligation to check each new prescription against the patient's medication profile for drug-drug interactions, drug-disease contraindications, drug-allergy conflicts, therapeutic duplication, incorrect dosage, and incorrect prescription duration; unlicensed practitioners who dispense prescriptions without performing CBP-required DUR checks expose patients to drug interaction harms (particularly the FDA Black Box Warning opioid-benzodiazepine combination, which requires specific pharmacist counseling under 16 CCR § 1707.2 — counseling that an unlicensed practitioner cannot lawfully provide); (b) mandatory consultation failures under 16 CCR § 1707.2 — CBP-licensed pharmacists are required to make a good-faith offer of consultation to each patient receiving a new prescription and to provide consultation on drug name, purpose, dosage, route of administration, duration, common side effects, drug interactions, storage requirements, and refill information; unlicensed practitioners dispensing without consultation violate both § 4060 (licensure) and 16 CCR § 1707.2 (consultation standard), reinforcing the CLRA § 1770(a)(5) misrepresentation of service characteristics predicate; (c) compounding potency failures — HRT preparations, pain management topicals, and other compounded medications require analytical potency testing (High-Performance Liquid Chromatography [HPLC] or equivalent) to confirm that the active pharmaceutical ingredient (API) concentration matches the labeled strength; unlicensed compounders who lack CBP PHY entity licensure and USP <795> compliance infrastructure typically also lack API potency testing capabilities, exposing patients to subtherapeutic (no effect) or supratherapeutic (toxicity) preparations; (d) sterile compounding sterility failures — preparations intended for injection or ophthalmic use must meet USP <797> sterility standards requiring ISO-classified clean room environments, environmental monitoring, aseptic technique training, and media fill testing; unlicensed compounders without CBP PHY entity licensure and USP <797> compliance infrastructure expose patients to bacterially or fungally contaminated injectable preparations.

Billing Gap 2 — Active Litigation — Discovery from Unlicensed Pharmacist and Pharmacy Entity, Medical Expert Coordination, DEA and CBP Enforcement Record Integration, and Compounding Liability Development (4.50 hrs/yr = $1,350–$2,250)

The second billing gap arises from the active litigation phase — from Tyler Odyssey complaint through trial or settlement — during which the attorney conducts discovery from both the unlicensed pharmacy practitioner and the operating pharmacy entity, coordinates with medical and pharmacology experts on DUR failure and compounding liability, integrates DEA enforcement records and CBP administrative accusation records, and develops the adulteration and misbranding claims (Health and Safety Code §§ 111295, 111330) in compounding cases.

• Conducting discovery from unlicensed pharmacy practitioner: dispensing logs, prescription records, compounding worksheets (Master Formula Records [MFRs] and Compounding Records [CRs]), patient medication profiles, DEA 222 order forms for Schedule II substances, DEA CURES 2.0 records, and any CBP license application history (including any prior CBP Accusation or Citation indicating CBP knowledge of unlicensed practice): the attorney conducts comprehensive discovery targeting the defendant's dispensing and compounding records; from the individual defendant practitioner, the attorney seeks: dispensing logs for the period covered by the challenged transactions — identifying all prescriptions dispensed to the patient plaintiff and other similarly situated patients, establishing the scope of the unlicensed practice and the universe of patients potentially harmed; compounding worksheets — specifically Master Formula Records (MFRs, the template for each compounding formulation listing API identity, strength, quantity, Beyond Use Date [BUD] determination basis, and USP standard reference) and Compounding Records (CRs, the batch-specific documentation for each compounded lot showing actual ingredients used, lot numbers, quantities, environmental monitoring data [for sterile preparations], potency testing results [if any], and dispensing information); patient medication profiles — the complete medication record for each patient showing all prescriptions dispensed, including any co-prescriptions triggering drug-drug interaction DUR screening obligations; DEA 222 order forms for Schedule II substances (the official DEA form required for each Schedule II controlled substance purchase, maintained under 21 C.F.R. § 1305.11) — confirming both the identity and quantity of Schedule II substances received by the defendant for dispensing and any discrepancies between received quantities and dispensed quantities suggesting drug diversion; DEA CURES 2.0 records — the California Controlled Substance Utilization Review and Evaluation System records maintained by DHCS (Department of Health Care Services) confirming controlled substance prescription dispensing by the defendant to the plaintiff and other patients; and any prior CBP Citation or Accusation served on the defendant by CBP — establishing that CBP previously investigated or disciplined the defendant for § 4060 violations, supporting enhanced Ketchum multiplier arguments based on the defendant's awareness of the unlicensed status and continued practice.
• Coordinating with pharmacology expert (PharmD or RPh expert witness) for DUR failure analysis — documenting drug-drug interaction failures (including opioid-benzodiazepine co-dispensing without Black Box Warning consultation under 16 CCR § 1707.2), compounding potency and sterility expert analysis (including Beyond Use Date determinations, USP <795>/<797> compliance assessment, and analytical potency testing report review), and prescriber verification failures in telehealth-based controlled substance dispensing cases: the CLRA § 1780 / § 4060 unlicensed pharmacy practice claim is both a consumer protection and a professional standards claim — a licensed California PharmD or RPh expert witness is essential to document: (a) what DUR screening and mandatory consultation a CBP-licensed pharmacist would have performed for each challenged prescription, and what harm was caused by the defendant's failure to perform CBP-required DUR screening; (b) in compounding cases, the specific USP <795> or <797> compliance failures associated with the compounded preparations at issue (clean room deficiencies, environmental monitoring gaps, Beyond Use Date miscalculation, potency testing omissions, or sterility testing failures) and the physical harm categories those compliance failures created for the patient plaintiff; (c) in controlled substance dispensing cases, the specific 21 U.S.C. § 829 / § 4060 dual violation analysis — documenting both the DEA CSR absence and the CBP RPh license absence that created the dual-level unlicensed dispensing for each Schedule II–V controlled substance at issue; and (d) the nexus between the defendant's specific unlicensed practice and the patient's specific adverse health outcome — establishing medical causation for the physical injury damages claimed alongside the CLRA § 1780 mandatory fee entitlement.
• Integrating DEA administrative enforcement records (DEA Order to Show Cause, DEA Immediate Suspension Order, and DEA final revocation or surrender orders) and CBP administrative accusation records into the civil action — confirming § 4060 / 21 U.S.C. § 829 violation findings for collateral estoppel use in the CLRA § 1780 case and supporting the compounding adulteration and misbranding (Health and Safety Code §§ 111295, 111330) claim development: in cases where DEA has issued an Order to Show Cause or Immediate Suspension Order against the defendant's DEA registration — based on DEA findings of unlicensed controlled substance dispensing or diversion — the DEA administrative enforcement records are admissible in the civil CLRA § 1780 action as agency findings supporting the 21 U.S.C. § 829 violation predicate and corroborating the § 4060 California Pharmacy Law violation; a final DEA revocation order, once administratively final, may support collateral estoppel on the DEA CSR violation element in the civil action (Lucido v. Superior Court (1990) 51 Cal.3d 335), eliminating the need to re-litigate the federal controlled substance dispensing violation in the civil proceeding; similarly, CBP administrative Accusations filed by the California AG on CBP's behalf — and any CBP Final Orders resulting from administrative hearing proceedings under the Administrative Procedure Act — may support collateral estoppel on the § 4060 California Pharmacy Law violation in the civil action, establishing the unlicensed pharmacy practice predicate for the CLRA § 1780 claim without requiring re-litigation of the CBP licensure issue; in compounding cases, the attorney develops the adulteration and misbranding claims (Health and Safety Code § 111295 [adulterated drug or device] and § 111330 [misbranded drug or device]) as parallel causes of action to the CLRA § 1780 consumer protection claim — each compounded preparation dispensed by the unlicensed compounder without USP <795> or <797> compliance constitutes a separately adulterated drug or device under § 111295, and each preparation dispensed without the § 4076 prescription label requirements constitutes a separately misbranded drug or device under § 111330; the statutory penalties under Health and Safety Code § 111940 ($250–$500 per violation, enforceable by the California AG or local DA) serve as per-unit damages anchors for restitution and penalty calculations, establishing the economic harm baseline for the UCL § 17200 restitution claim and reinforcing the Ketchum multiplier argument based on the per-patient scale of unlicensed practice.

Billing Gap 3 — CLRA § 1780 Fee Petition — Ketchum Multiplier for PURE KETCHUM California Pharmacy Law Claim, CBP BreEZe Dual-Level Anchor Narrative, PLCM Group Affidavit, and Missouri v. Jenkins Fees-on-Fees (4.00 hrs/yr = $1,200–$2,000)

The third billing gap arises from the CLRA § 1780 mandatory attorney fee petition phase — from judgment through post-judgment fee petition briefing, PLCM Group affidavit preparation, Ketchum multiplier argument, and fees-on-fees recovery — encompassing all attorney time spent documenting the complete lodestar, establishing the CBP BreEZe dual-level secondary anchor narrative (individual RPh and PHY entity levels), briefing the PURE KETCHUM status with no Dague constraint, and integrating the compounding adulteration and misbranding liability narrative into the Ketchum multiplier argument.

• Documenting the complete CLRA § 1780 lodestar from CBP BreEZe search date (secondary anchor) through Tyler Odyssey complaint (primary anchor) and through judgment — including dual-level CBP BreEZe verification (individual RPh + PHY entity), DEA CSR verification for controlled substance cases, pharmacology expert coordination, and all pre-trial and trial preparation work — with the CBP BreEZe dual-level anchor narrative explaining the unique dual RPh-and-PHY entity verification required for unlicensed pharmacy practice cases: the CLRA § 1780 fee petition documents the complete lodestar beginning with the CBP BreEZe search — specifically, the dual-level CBP BreEZe verification (individual RPh license and PHY entity license) that establishes the secondary anchor at both the individual practitioner and operating entity levels — and proceeds through the full Tyler Odyssey complaint through judgment timeline; the fee petition narrative explains the unique characteristics of the CBP BreEZe dual-level secondary anchor: the CBP BreEZe module is the only DCA BreEZe module in the fee-petition-mechanics series that covers both individual practitioner licenses (RPh, CPhT, intern) and entity licenses (PHY pharmacies), requiring dual-level verification to confirm both the individual dispensing practitioner's unlicensed status and the operating pharmacy entity's unlicensed status; the Pharmacist-in-Charge (PIC) identification recorded in each PHY entity's BreEZe record establishes the organizational accountability link between the PHY entity license and the individual RPh licensee responsible for the dispensing activities; in controlled substance dispensing cases, the fee petition narrative also documents the DEA CSR verification — confirming the simultaneous federal 21 U.S.C. § 829 violation and California § 4060 violation, and explicitly confirming the PURE KETCHUM status (no federal statute provides a private right of action with mandatory fee-shifting for controlled substance dispensing victims); in compounding cases, the fee petition narrative documents the adulteration and misbranding liability (Health and Safety Code §§ 111295, 111330) as reinforcing CLRA § 1780 predicates and explains the compounding harm spectrum (potency failures, sterility failures, BUD violations, and cross-contamination risks) as supporting grounds for the Ketchum multiplier's complexity premium.
• Briefing the Ketchum multiplier for PURE KETCHUM Bus. & Prof. Code § 4060 / CLRA § 1780 claims: the pharmacy practice complexity premium (requiring simultaneous California Pharmacy Law, DEA controlled substance regulatory analysis, pharmacology expert coordination, and compounding USP standard proficiency); the PURE KETCHUM status with no Dague constraint (no federal statute provides private fee-shifting for unlicensed pharmacy practice victims); the PLCM Group market rate analysis for solo California consumer protection attorneys handling CBP § 4060 unlicensed pharmacy practice claims with controlled substance DUR analysis and compounding liability: the Ketchum v. Moses (24 Cal.4th 1122 (2001)) contingency multiplier analysis for § 4060 / CLRA § 1780 unlicensed pharmacy practice cases has several compelling dimensions: (a) the pharmacy practice complexity premium — handling a CLRA § 1780 unlicensed pharmacy claim requires not only standard consumer protection plaintiff expertise but also proficiency in California Pharmacy Law (Bus. & Prof. Code §§ 4000–4427), CBP administrative enforcement procedures (CBP Accusation process, CBP Final Order enforcement), DEA controlled substance regulatory law (21 U.S.C. § 829, DEA CSR verification, CURES 2.0 records), pharmacology expert coordination (PharmD or RPh expert witness proficiency in DUR standards, 16 CCR § 1707.2 consultation requirements, and USP <795>/<797> compounding compliance standards), and compounding liability (Health and Safety Code §§ 111295, 111330 adulteration and misbranding claims with USP standard compliance analysis) — a multi-discipline complexity that commands a premium above the standard California consumer protection plaintiff bar rate; (b) the PURE KETCHUM status with no Dague constraint — the entire CLRA § 1780 lodestar is eligible for the full contingency multiplier under Ketchum without any Dague constraint, because no federal statute (not the CSA, not the DQSA, not the Ryan Haight Act, not the FDCA) creates a parallel mandatory fee-shifting mechanism for patients harmed by unlicensed California pharmacy practice; (c) the PLCM Group Inc. v. Drexler (22 Cal.4th 1084 (2000)) market rate analysis documenting the prevailing hourly rate in the California legal community for a solo practitioner handling CLRA § 1780 / § 4060 unlicensed pharmacy practice claims with DEA controlled substance regulatory analysis, pharmacology expert coordination, and USP compounding standard proficiency; and (d) the contingency risk premium — CLRA § 1780 / § 4060 unlicensed pharmacy cases are commonly handled on contingency because patient-plaintiffs typically lack resources to pay hourly rates for complex healthcare litigation, requiring the attorney to advance costs through expert retention, discovery, DEA enforcement coordination, and potentially trial without payment, justifying a meaningful Ketchum multiplier.
• Missouri v. Jenkins fees-on-fees recovery for all fee petition preparation time — the CBP BreEZe dual-level anchor narrative, the DEA CSR verification section, the compounding adulteration and misbranding liability narrative, the Ketchum multiplier brief, the PLCM Group affidavit, and all reply briefing responding to the defendant's opposition: Missouri v. Jenkins (491 U.S. 274 (1989)) establishes that attorney time spent preparing the CLRA § 1780 fee petition is itself compensable as fees-on-fees — encompassing all time the attorney spent: drafting the CBP BreEZe dual-level anchor establishment narrative (explaining the dual RPh license and PHY entity license verification, the Pharmacist-in-Charge identification, the CBP BreEZe module's distinction from all other DCA healing arts board BreEZe modules in the series); in controlled substance cases, drafting the DEA CSR verification section (explaining the simultaneous § 4060 / 21 U.S.C. § 829 dual violation and confirming the PURE KETCHUM status with no federal fee-shifting statute); in compounding cases, drafting the adulteration and misbranding liability narrative (documenting the USP <795>/<797> compliance failures, the Health and Safety Code §§ 111295/111330 predicate violations, and the per-preparation penalty analysis under Health and Safety Code § 111940); preparing the Ketchum multiplier brief (documenting the pharmacy practice complexity premium, the PURE KETCHUM status, and the PLCM Group market rate analysis); preparing the PLCM Group Inc. v. Drexler (22 Cal.4th 1084 (2000)) market rate affidavit; and drafting reply briefing responding to the defendant's opposition, including any challenge to the CBP BreEZe dual-level anchor date, the DEA CSR verification narrative, the compounding liability analysis, or the Ketchum multiplier; all fees-on-fees time is recoverable at the same lodestar rate per settled California CLRA § 1780(e) law.

Total Annual Billing Gap — Three-Gap Summary

• Gap 1 (CBP BreEZe search, DEA CSR verification, § 4060 analysis, DUR and compounding harm assessment): 5.25 hrs = $1,575–$2,625/yr
• Gap 2 (active litigation, pharmacology expert coordination, DEA/CBP enforcement integration, compounding liability): 4.50 hrs = $1,350–$2,250/yr
• Gap 3 (CLRA § 1780 fee petition, Ketchum, PLCM Group, dual-level anchor narrative, fees-on-fees): 4.00 hrs = $1,200–$2,000/yr
• Total: 13.75 hrs = $4,125–$6,875/yr untracked at $300–$500/hr median California solo practitioner rate

Related California Attorney Fee Petition Pages

• California Medical Board — Bus. & Prof. Code § 2052
• California Physician Assistant Board — Bus. & Prof. Code § 3526
• California Naturopathic Medicine Committee — Bus. & Prof. Code § 3637